These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 18509133)

  • 1. Acute lower respiratory tract infection.
    Eisenhut M
    N Engl J Med; 2008 May; 358(22):2413-4; author reply 2414. PubMed ID: 18509133
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuraminidase antibodies and H5N1: geographic-dependent influenza epidemiology could determine cross-protection against emerging strains.
    Bermejo-Martin JF; Kelvin DJ; Guan Y; Chen H; Perez-Breña P; Casas I; Arranz E; de Lejarazu RO
    PLoS Med; 2007 Jun; 4(6):e212. PubMed ID: 17593897
    [No Abstract]   [Full Text] [Related]  

  • 3. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
    Itoh Y; Ozaki H; Tsuchiya H; Okamoto K; Torii R; Sakoda Y; Kawaoka Y; Ogasawara K; Kida H
    Vaccine; 2008 Jan; 26(4):562-72. PubMed ID: 18164788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Host species barriers to influenza virus infections.
    Kuiken T; Holmes EC; McCauley J; Rimmelzwaan GF; Williams CS; Grenfell BT
    Science; 2006 Apr; 312(5772):394-7. PubMed ID: 16627737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One step closer to universal influenza epitopes.
    Li OT; Poon LL
    Expert Rev Anti Infect Ther; 2009 Aug; 7(6):687-90. PubMed ID: 19681695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prior infection with an H1N1 swine influenza virus partially protects pigs against a low pathogenic H5N1 avian influenza virus.
    Van Reeth K; Braeckmans D; Cox E; Van Borm S; van den Berg T; Goddeeris B; De Vleeschauwer A
    Vaccine; 2009 Oct; 27(45):6330-9. PubMed ID: 19840669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza virus NS1 protein protects against lymphohematopoietic pathogenesis in an in vivo mouse model.
    Hyland L; Webby R; Sandbulte MR; Clarke B; Hou S
    Virology; 2006 May; 349(1):156-63. PubMed ID: 16545418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.
    Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
    J Infect Dis; 2009 Feb; 199(3):405-13. PubMed ID: 19061423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathology in dogs with experimental canine H3N2 influenza virus infection.
    Jung K; Lee CS; Kang BK; Park BK; Oh JS; Song DS
    Res Vet Sci; 2010 Jun; 88(3):523-7. PubMed ID: 19963232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.
    Sandbulte MR; Jimenez GS; Boon AC; Smith LR; Treanor JJ; Webby RJ
    PLoS Med; 2007 Feb; 4(2):e59. PubMed ID: 17298168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cytokine storm in avian influenza].
    Us D
    Mikrobiyol Bul; 2008 Apr; 42(2):365-80. PubMed ID: 18697437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
    Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
    Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.
    Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
    Vaccine; 2009 Oct; 27(45):6296-9. PubMed ID: 19840663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for developing vaccines against H5N1 influenza A viruses.
    Horimoto T; Kawaoka Y
    Trends Mol Med; 2006 Nov; 12(11):506-14. PubMed ID: 17011235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ferrets and the challenges of H5N1 vaccine formulation.
    Hampson AW
    J Infect Dis; 2006 Jul; 194(2):143-5. PubMed ID: 16779718
    [No Abstract]   [Full Text] [Related]  

  • 16. [Influenza type A (H5N1) virus infection].
    Engin A
    Mikrobiyol Bul; 2007 Jul; 41(3):485-94. PubMed ID: 17933264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
    Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
    J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Respiratory virus antibodies in human sera from different regions of the world].
    Taylor-Robinson D
    Bol Oficina Sanit Panam; 1966 Sep; 61(3):237-53. PubMed ID: 4288913
    [No Abstract]   [Full Text] [Related]  

  • 19. Influenza vaccines and vaccination strategies in birds.
    van den Berg T; Lambrecht B; Marché S; Steensels M; Van Borm S; Bublot M
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):121-65. PubMed ID: 17889937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [H5N1: vaccine solutions in men and animals].
    Durant MP;
    Sante; 2006; 16(2):135-8. PubMed ID: 17180763
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.